Coronavirus staff guidance University Hospitals Birmingham NHS Foundation Trust

Last updated: 24 January 2025 at 14:50

Valproate medicines (for any indication) are contraindicated in girls and women of childbearing potential unless the conditions of the Pregnancy Prevention Programme (PPP) are fulfilled.

During the current coronavirus (COVID-19) pandemic, for girls and women of childbearing potential taking valproate, the MHRA has issued temporary advice to support adherence to the PPP requirements, in addition to ensuring that these requirements can be met safely.

The advice relates to considerations in consultations where valproate is being initiated, the annual review of existing patients, pregnancy testing and calls for reporting via the Yellow Card website.

For detailed information, please see the "downloads" section.